Objectives. To investigate the efficacy of IA CS (IAC) therapy in single and multiple joints in children with JIA and to seek for predictors of synovitis flare.
Introduction
IA CS (IAC) injection is widely used in children with JIA to induce prompt relief of symptoms of active synovitis, including pain, swelling and impaired joint mobility [13] . This mode of therapy is generally considered for the treatment of children with arthritis in a small number of joints, particularly large joints, or in cases when only few joints remain actively inflamed during treatment with systemic DMARDs, such as MTX. Nowadays, it is thought that many paediatric rheumatologists are using IACs as their first approach in oligoarticular JIA [4, 5] . In children with this subtype, local IAC therapy has been shown to enable correction of joint contractures, prevention of leg-length discrepancy, discontinuation of oral medications, resolution of Baker's cysts and improvement of tenosynovitis [6, 7] .
However, the strategy of performing multiple IAC injections is used by some clinicians in children with polyarthritis to induce prompt remission of synovitis, while simultaneously initiating therapy with DMARD and/or biologic agents [8] . This approach is regarded as an alternative to systemic CSs to pursue the so-called bridge effect; i.e. to achieve a quick control of inflammatory symptoms while awaiting the full therapeutic effect of a DMARD or biologic medication. Multiple IAC injections have the potential advantage of avoiding many side effects of systemic CSs and selectively targeting the inflamed joints. A recent survey among paediatric rheumatologists in the USA and Canada has shown that 15% had performed more than 10 IAC injections in a single paediatric patient at one time [9] . However, the therapeutic effectiveness of multiple IAC injections has seldom been investigated in JIA. As a result, the place of multiple IAC injections in the current disease management remains unclear and controversial.
Knowledge of factors affecting the outcome of IAC injections may help to select appropriate treatment options in individual patients and provide counselling to parents and patients. A number of predictors of the effectiveness of IAC therapy have been reported (reviewed in [4, 5, 10] ). Factors associated with beneficial response include first injection into an individual joint, the oligoarthritis subtype, injection in the knee or upper extremity joints, shorter disease duration, younger age, male gender, concomitant treatment with MTX, injection under general anaesthesia, higher ESR and higher levels of MMP-3, IL-6 and IL-10 in the SF. Systemic arthritis, injection in the hip, higher count of SF polymorphonuclear leucocytes and carrying the À173*C allele of macrophage migration inhibitory factor (MIF) have all been identified as predictors of poorer efficacy. However, reported studies are difficult to compare and interpret due to differences in the disease subtypes included, type and number of joints injected, definitions of improvement used, concomitant systemic therapy, time frame adopted to assess treatment response or failure and predictors investigated. Furthermore, prognostic factors have rarely been examined by stratifying patients by the number of injections performed. The objective of the present study was to investigate the efficacy and seek for outcome predictors of IAC injections in single and multiple joints in children with JIA.
Patients and methods

Patient selection
The clinical charts of all consecutive patients who met the ILAR criteria for JIA [11] , had received their first IAC injection at study centres between January 2002 and December 2008 and had a minimum follow-up of 6 months after the IAC injection were reviewed retrospectively. Patients were excluded if they had received an IAC injection elsewhere in the preceding 3 months. Patients who had received a CS injection only in tendon sheaths were also excluded. The study was approved by the Ethical committee of the Istituto G. Gaslini, Genova, Italy.
Injection procedure
Children under the age of 6 years who had more than three to four joints injected at one time were injected in the operatory room under general anaesthesia. Some less cooperative children received conscious sedation with oral or rectal midazolam in the day-care unit of the paediatric rheumatology divisions. Older children, who were deemed able to cooperate, were just given a local anaesthetic before needle insertion, using an eutectic mixture of lidocaine/prilocaine cream 5%, containing 2.5% of each drug, applied topically under occlusion. After removal of lidocaine/prilocaine cream, an additional anaesthetic effect was pursued through local administration of ice (ethyl chloride) spray. Following strict antiseptic preparation of the skin, the joint fluid was aspirated (whenever possible) and the CS medication was injected. In the case of triamcinolone hexacetonide (TH) injection (see below), before removing the needle from the joint space, the needle track was flushed with 1% lidocaine to avoid spillage of CSs to the surrounding tissue. More than 90% of the injections were performed by the same paediatric rheumatologist (A.R.). A fraction (1020%) of injections in subtalar joints and all injections in intertarsal joints were performed under US guidance. Injections into the hip were made using fluoroscopy to control for correct position of the needle. All patients and their parents were instructed to avoid activity or weight bearing for a period of 24 h (72 h in the case of hip injection).
CS preparations and dosage
The CS used was TH for large joints and methylprednisolone acetate (MPA) for small or difficult to access joints. The dose of TH injected was 1 mg/kg (maximum 40 mg) in knees, shoulders and hips, 0.75 mg/kg (maximum 30 mg) in ankles and elbows and 0.250.5 mg/kg, depending on child's size (maximum 20 mg) in wrists. The dose of MPA injected was 2040 mg in subtalar and intertarsal joints and 510 mg in small hand and foot joints. The more soluble preparation of MPA was chosen to inject small or difficult to access joints to avoid the high risk of extra-capsular leakage and s.c. tissue atrophy related to the administration of TH [4, 5, 10] . In some patients, triamcinolone acetonide was used instead of TH at the time of the first IAC injection, due to the temporary shortage of TH (200304) . In these patients, the first injection performed after TH that became available again was considered as the first IAC injection.
Outcome assessment
Based on the number of injected joints, patients were divided in the following three groups: one joint injected (single injection); two joints injected (double injection); three or more joints injected (multiple injection). In each patient, the follow-up period after the IAC injection was censored at the time when one of the following four events occurred: (i) flare of synovitis in injected joints; (ii) flare of synovitis in injected and uninjected (i.e. previously unaffected) joints; (iii) follow-up visit with continued remission of synovitis in injected joints, but with recurrence of synovitis in uninjected joints, that required a major therapeutic intervention (i.e. an IAC injection or the start of a systemic therapy with DMARDs, biologic medications or CSs). It was felt that the therapeutic intervention made to treat synovitis in uninjected joints made it impossible to establish whether the subsequent persistence of remission of synovitis in injected joints was due to the effect of the initial IAC injection or the therapeutic intervention itself; and (iv) last follow-up visit with continued remission of synovitis in injected and uninjected joints. For the purposes of the analysis, Events (i) and (ii) were considered altogether as flare of synovitis in injected joints, whereas Events (iii) and (iv) were considered altogether as remission of synovitis in injected joints. Flare of synovitis was defined as recurrence of clinical signs of joint inflammation, including swelling, pain on motion/tenderness and restricted motion, which required a major therapeutic intervention (as above defined). Remission of synovitis was defined as absence of all clinical signs of joint inflammation.
Predictor assessment
The following independent (predictor) variables were recorded at the time of IAC injection: sex, age at disease onset, ILAR category, age and disease duration, ANA status, previous diagnosis of iridocyclitis, general anaesthesia, number and type of injected joints, ESR (Westergren method), CRP (immunoturbidimetric assay) and concomitant therapy (either ongoing or newly started) with MTX, biologics and systemic CSs. Patients were defined as ANA positive if they had at least two positive determinations at a titre 51 : 160, as previously reported [12] .
Statistics
Descriptive statistics were reported in terms of medians and ranges for continuous variables and in terms of absolute frequencies and percentages for categorical variables. Comparison of quantitative variables in two groups or multiple groups was made by means of the MannWhitney U-test or the non-parametric analysis of variance (KruskalWallis test), respectively. Comparison of qualitative data was performed by means of the 2 -test, or the Fisher's exact test in case of expected frequencies <5. For each category of risk factors tested, the number of patients with flare of synovitis, the median time to flare and the incidence rate of flare were calculated. Survival analysis, with flare of synovitis as the event of interest, in each group was conducted by means of the KaplanMeier method. Survival curves were compared by the log-rank test. Factors significantly associated with time to flare were then tested in a Cox proportional hazards regression model. The likelihood ratio (LR) test was used for comparisons and a P < 0.05 was considered as statistically significant. The software Statistica (release 6.0, StatSoft Corporation, Tulsa, OK, USA) and Stata (release 7.0) were used for data analyses.
Results
A total of 440 children with JIA who received their first IAC injection at the study units were included in the study. These patients were part of a whole series of around 900 JIA patients seen at the study units in the study period. Eighteen patients were excluded because they had received an IAC injection elsewhere in the 3 months preceding the first injection at the study units. The 440 patients had a total of 965 joints injected. Two hundred and fifteen (48.9%) patients were injected in one joint, 107 (24.3%) were injected in two joints and 118 (26.8%) were injected in three or more joints. The maximum number of joints injected in a single patient was 20. Table 1 shows the main demographic and clinical features of study patients, divided by the number of injected joints. As compared with patients who were injected in one or two joints, patients who had an injection in three or more joints had a younger age at disease onset, were younger at the time of injection and had more frequently systemic arthritis or RF-negative polyarthritis. Patients who received a single injection had more frequently persistent oligoarthritis and had lower values of ESR and CRP than did patients who underwent a double or multiple injection. Female prevalence, percentage of the extended oligoarthritis subtype, ANA status and disease duration at the time of injection were comparable among patients injected in single, double or multiple joints. As expected, patients who had injection in three or more joints had undergone more frequently general anaesthesia and were more frequently treated or newly started with MTX, biologic medications or systemic CSs. The duration of follow-up was comparable among patients who received single or multiple injections. Of the 24 (5.5%) patients who received biologics, 17 were given etanercept, 4 anakinra and 3 infliximab. The ILAR category of these patients was systemic arthritis in 12, extended oligoarthritis in 5, RF-negative polyarthritis in 4, enthesitis-related arthritis in 2 and PsA in 1.
The type and number of injected joints are presented in Table 2 . The knee was the most frequently injected joint, with similar rates in all patient groups. The ankle was second in order of frequency among injected joints. However, the ratio of knee : ankle injection was around 10 : 1 in patients who were injected in a single joint, but decreased to around 2 : 1 in patients who were injected in two joints, and was close to 1 : 1 in patients who were injected in three or more joints. The elbow, wrist and small hand and foot joints were injected with noticeable frequency only in patients who received a multiple injection. The hip was injected in very few patients and no patient underwent injection in the TM joints.
At 6 months after the IAC injection, remission of synovitis in all joints (injected and uninjected) was recorded in 65.1, 56.1 and 65.2% of patients who had received a single, double or multiple injection, respectively. An additional proportion of patients, which was sizeable among those injected in one or two joints (17.7 and 20.6%, respectively), but very small among those injected in three or more joints (1.7%), had remission of synovitis in all injected joints, but experienced flare of synovitis in one or more uninjected joints.
The survival analysis, with flare of synovitis as the event of interest, in patients who received a single, double or multiple injection is presented in Fig. 1 injected in two or three or more joints than in those injected in a single joint, with patients injected in two or three or more joints joints being comparable. The cumulative probability of not experiencing a synovitis flare for patients injected in one, two, or three or more joints was 70, 45 and 44%, respectively, at 1 year; 61, 32 and 30%, respectively, at 2 years; and 37, 22 and 19%, respectively, at 3 years. Looking at the slope of the curve, it appears that the probability of flare is the maximum for all groups in the first year after the IAC injection and decreases steadily thereafter. Interestingly, after the first year the relapse rate between patients who underwent single or multiple injections becomes similar. The drop of the curve to 0 in patients injected in three or more joints after 45 years depends, at least partially, to the fact that we began to perform more extensively multiple IAC injections in the years 200304. Of the 324 patients who had a flare of synovitis in injected or uninjected joints, 240 (74.1%) underwent a repeated IAC injection. The survival analysis, with flare of synovitis as the event of interest, by ILAR subtype of JIA is shown in Fig. 2 . The log-rank test revealed that patients with systemic arthritis developed a synovitis flare more frequently and precociously than did patients with polyarthritis and oligoarthritis. The cumulative probability of not experiencing a flare of synovitis in patients with systemic arthritis, polyarthritis and oligoarthritis was 25, 48 and 67%, respectively, at 1 year; 12, 34 and 57%, respectively, at 2 years; and 0, 21 and 37%, respectively, at 3 years. Table 3 presents, for each risk factor category, the number of patients with flare of synovitis out of the total number of patients in the risk factor category, the median survival time and the incidence rate of flare. Factors associated with a greater risk of flare and a shorter survival time were a greater number of injected joints, the ILAR category (with the risk being greatest for systemic arthritis and the lowest for oligoarthritis), a negative ANA status, the injection in the ankle and elbow joint, an increase in ESR and CRP values and systemic CS administration. When all these variables were included in a Cox proportional hazards regression model, the results showed that a positive CRP, a negative ANA status and the injection of the ankle joint were the only parameters associated with the risk of flare of synovitis in injected joints (Table 4) . In 69 patients who were taking MTX at the time of the IAC injection, the median duration of MTX therapy was shorter in patients who had a relapse of synovitis in injected joints (n = 37) than in those who did not (n = 32) (1.1 vs 2.8 years; P = 0.043).
The most common side effect was skin hypopigmentation or s.c. atrophy at the site of injection. However, this adverse event, which occurred most frequently in the wrist joint, was seen in <2% of patients. A number of patients who underwent multiple IAC injections developed flushing or redness of the cheeks 2448 h after the procedure as a result of systemic CS absorption. However, no case of overt or symptomatic Cushingoid syndrome was observed. Side effects of sedation most commonly encountered included confused state with irritability, drowsiness and transient decrease in blood pressure or oxygenation. No serious adverse events or deaths occurred.
Discussion
IAC injection remains an important therapeutic option for children with JIA, even in the biologic era. However, the place of this treatment modality in the current management of JIA is still uncertain. A recent survey of practitioners in the USA has shown considerable variation in the initial treatment of knee monoarthritis in children with JIA: only 27% of 129 respondents recommended initial IAC injection at disease presentation, whereas the majority (63%) advised a trial of NSAID, followed by IAC administration in case of failure; the remainder (10%) preferred initial NSAID administration, followed by MTX or SSZ instead of IACs [13] . It is conceivable that should the Patients with RF-negative polyarthritis, RF-positive polyarthritis and extended oligoarthritis combined. b Patients with persistent oligoarthritis, PsA, enthesitis-related arthritis and undifferentiated arthritis combined. *P-value refers to the log-rank test. E/N: number of patients who experienced the event (flare of synovitis)/number of patients with the risk factor category.
indication to multiple joint injections be surveyed, disagreement would be even more pronounced. These disparities clearly reflect the lack of evidence-based information to guide IAC administration in JIA.
Our analysis involved the largest number of IAC-treated JIA patients studied so far. We examined only the outcome of the first IAC injection for sake of uniformity and because we sought to investigate the role of this therapeutic intervention as early treatment. Our patients had, on average, early disease, as shown by their median disease duration of 0.8 years. We examined separately single, double and multiple IAC injections to obtain information useful to define their relative indication in disease management. Our patient series had the typical characteristics of the Italian JIA population, which is overly represented by children with early onset, asymmetric arthritis and positive ANA status [12, 14, 15] . Children who received a multiple injection had an earlier onset age and were much younger at the time of the procedure than children who underwent a single or double injection. Most of these children were candidate to a multiple IAC injection as bridge therapy, aimed to achieve a quick control of inflammatory symptoms, while awaiting the full therapeutic effect of MTX, as an alternative to systemic CS administration or because etanercept could not be prescribed because of an age < 4 years.
As expected, patients injected in a single joint, which was the knee in 89% of instances, had a lesser likelihood of experiencing a flare of synovitis and a longer survival time without flare than did patients who underwent a double or multiple injection. Injection in the knee joint was previously found to predict a favourable outcome of IAC therapy [16] . Unexpectedly, patients injected in two or three or more joints had a comparable risk of flare and survival time without flare. This finding suggests that injecting two or three or more joints makes no difference in terms of treatment outcome. A sizable percentage of patients, particularly among those who were injected in one or two joints, had a relapse of arthritis in previously unaffected joints while synovitis was in continued remission in injected joints. This observation implies that IAC therapy may not be able to prevent extension of arthritis to unaffected joints. The cumulative probability of survival without synovitis flare at 1, 2 and 3 years among patients who underwent a multiple IAC injection was 44, 30 and 19%, respectively, which indicates that this therapeutic modality is able to induce a long-lasting remission in a substantial proportion of patients. IAC therapy in multiple joints deserves, thus, consideration as initial remissioninducing therapy in children with polyarthritis.
An important finding of our study is that the risk of synovitis flare was the maximum in the first year after the IAC injection, irrespective of the number of joints injected, and decreased steadily thereafter. Importantly, after the first year, the probability of flare became similar in patients who underwent a single, double or multiple injection. These observations suggest that in children with JIA who are administered IAC therapy, the first year after the injection constitutes a therapeutic window, in which the combination of IAC injection with a systemic therapeutic intervention (with MTX or biologic medications) may help to maximize the long-term benefit.
As reported by other investigators [17] , we found that the risk of flare and time to flare were greatest and shortest, respectively, in patients with systemic arthritis and lowest and longest, respectively, in patients with oligoarthritis. This finding may be partially related to patients with oligoarthritis being more likely to having been injected only in a single joint. Other factors associated with flare of synovitis identified in univariate analysis were the injection in two or three or more joints or in the ankle joint, a negative ANA status, a higher level of acute-phase reactants and concomitant systemic CS administration. On Cox regression analysis, the strongest flare predictors were increased CRP value, negative ANA status and the injection in the ankle joint. Importantly, that the number of IAC injections did not enter the best fitting model implies that these predictors are of value across children injected in single or multiple joints. Unlike previous studies (reviewed in [4, 5, 10] ), we did not find an association between a greater flare rate and preceding IAC therapy, shorter disease duration, younger age, male gender, general anaesthesia or concomitant MTX therapy. The lack of association with MTX administration should be regarded with caution, however, as our study was not controlled. It is likely that MTX was prescribed to the most ill patients, who could be more susceptible to develop a disease flare. The role of MTX in enhancing the effectiveness of IAC therapy needs to be explored in a controlled trial. Notably, among the 69 patients who were receiving MTX at the time of the IAC injection, those who did not experience a flare of synovitis tended to have received MTX for a longer period than did patients who experienced a flare of synovitis. Recently, early suppression of synovitis in adult patients with RA by an aggressive DMARD step-up treatment combined with IA betamethasone was found to result in excellent clinical response and disease control at 2 years, and in suppression of the rate of radiographic progression [18] . Whether IAC therapy has a diseasemodifying potential in children with JIA is unknown. Our study should be interpreted in the light of some potential limitations, primarily its retrospective nature. A retrospective analysis is subject to missing and possibly erroneous data. We should acknowledge that the choice of censoring the follow-up at the time when patients had a relapse of arthritis in uninjected (i.e. previously unaffected) joints, while synovitis was still in remission in injected joints might have led to increase the relapse rate and shorten the time to flare, particularly among patients who received a single or double injection. Very few patients underwent injection in the hip joints and none was injected in the TM joints. Thus, our results are of no value for IAC administration in these joints. Our policy of using MPA instead of TH for small and difficult to access joints may hamper comparability of our findings with those of investigators who inject these joints with TH.
In summary, we found that IAC therapy was able to induce sustained remission of joint synovitis in a substantial percentage of patients injected either in single or multiple joints, with a good safety profile. The positive results obtained in patients who underwent multiple IAC injection suggest that this procedure represents a powerful and safe remission-inducing therapeutic strategy for children with polyarticular JIA. A positive CRP, a negative ANA status and the injection in the ankle were the strongest predictors of relapse of synovitis in injected joints. A controlled trial of IAC therapy in combination with MTX or, perhaps, biologics is warranted.
Rheumatology key messages
. IAC injection remains an important therapeutic option for children with JIA. . The place of IAC therapy in the current management of JIA is unclear. . IAC therapy in single or multiple joints induces sustained remission of synovitis in a substantial proportion of patients.
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